Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir

AIDS Patient Care and STDs

Volumn 17, Issue 9, 2003, Pages 443-445

  González de Requena, Daniel ^a   Blanco, Francisco ^b   Garcia Benayas, Teresa ^b   Jiménez Nácher, Inmaculada ^a   González Lahoz, Juan ^b   Soriano, Vincent ^b  

^a Pharmacology Unit   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; SALVAGE THERAPY;

EID: 19244373816     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/108729103322395465     Document Type: Article

References (11)

1. Murphy R, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48 weeks results. AIDS 2001;15:F1-F9.
2. Johnson M, Beall G, Badley A, et al. ABT-378/ritonavir versus nelfinavir in antiretroviral naive subjects: week 48 comparison in a phase III blinded randomised clinical trial (study 863). AIDS 2000;14(Suppl 4):7.
3. Benson C, Deeks S, Brun S, et al. Safety and antiviral activity at week 48 of lopinavir/ritonavir plus nevirapine and two NRTI in HTV-1-infected protease inhibitor-experienced patients. J Infect Dis 2002;185: 599-607.
4. Rockstroh J, Brun S, Sykte J, et al. ABT-378/ritonavir and efavirenz: one year safety/efficacy evaluation in multiple PI-experienced patients (study 957). AIDS 2000;14(Suppl 4):29.
5. De Mendoza C, Martin-Carbonero L, Barreiro P, et al. Salvage treatment with lopinavir/ritonavir in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002;3:304-309.
6. Boffito M, Amaudo I, Raiteri R, et al. Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. AIDS 2002;16: 2081-2083.
7. Padilla S, Navarro A, Gallego J, et al. The relationship between lipid elevations and lopinavir concentrations in HIV-infected patients, 42nd ICAAC, San Diego, September 2002. Abstract H-1915.
8. Calboreanu A, Dimet J, Treluyer J, et al. Relation between Lopinavir plasma blood concentrations and hypertriglyceridemia in naive and protease inhibitors-experienced patients. 10th CROI, Boston, February 2003. Abstract 526.
9. Titier K, Lagrange F, Péhourcq F, et al. High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. Ther Drug Monitor 2002;24:417-424.
10. Pradier C, Sabin C, Friis-Moller N, et al. Lipid profiles on therapy with PI. The D:A:D (data collection on adverse events of anti-HIV drugs) study. Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2002. Abstract PL12.1.
11. Shafran S, Mashinter L, Roberts S, et al. The effect of ritonavir (RTV) 100 mg bid on serum lipid profiles. Sixth International Congress on Drug Therapy in HIV Infection, Glasgow, November 2002. Abstract P129.